A high-quality health benefits platform with four consecutive earnings beats and free cash flow running at 161% of net income is temporarily weighed down by a confirmed price downtrend and a death cross; roughly 20% room to the analyst-consensus target and a 2.3-to-1 favorable risk/reward suggest the setup can reward patience once momentum recovers, though the technical block and single-product concentration risk make the near-term path uncertain.
Thesis pillars
- Cash Generative Quality Franchise→Stable
- Consistent Earnings Beat Streak→Stable
- Confirmed Technical Downtrend→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 17, 2026
HealthEquity, Inc. (HQY) Stock Analysis
Healthcare · Health Information Services
Hold if already holding. Not a fresh buy at $101.36, but acceptable to hold if already in. Reasons: Concentration risk — Product: HSAs and other CDBs; Thin upside margin: 7.1%.
HealthEquity administers HSAs and consumer-directed benefit accounts—17.8 million Total Accounts including 10.6 million HSAs with $36.5 billion in HSA Assets as of January 2026—and is the largest U.S. HSA provider by account count. Revenue comes from service fees, custodial fees... Read more
Hold if already holding. Not a fresh buy at $101.36, but acceptable to hold if already in. Reasons: Concentration risk — Product: HSAs and other CDBs; Thin upside margin: 7.1%. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.0/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, earnings proximity 32d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About HealthEquity, Inc.
About HealthEquity, Inc.
HealthEquity administered 17.8 million Total Accounts — 10.6 million HSAs holding $36.5 billion in HSA Assets and 7.2 million complementary CDB accounts — as of January 31, 2026, representing 20% of U.S. HSA Assets by market share per the 2025 Midyear Devenir HSA Research Report. The company ranked first among HSA providers by account count and second by assets. Platforms were integrated with more than 200 Network Partners as of the same date.
HealthEquity earns revenue from three sources: service fees charged to employer clients, Network Partners, and members for account administration; custodial fees earned from insurance company partners and federally insured Depository Partners holding HSA cash (approximately 48% of fiscal 2026 revenues); and interchange fees collected when members use payment cards (15% of fiscal 2026 revenues). The company reaches employers through a B2B2C channel, with Network Partners — health plans, benefits administrators, and retirement recordkeepers — distributing the HSA platform to their employee bases. In fiscal 2025, the company acquired the BenefitWallet HSA portfolio from Conduent Business Services, LLC, comprising roughly 616,000 HSAs and $2.7 billion in HSA Assets, for $425.0 million financed through its revolving credit facility and cash on hand. Direct competitors include Fidelity Investments, Webster Bank, and Optum Bank, a subsidiary of UnitedHealth Group.
Show full overview
HealthEquity's custodial revenue concentration in insurance company partners and Depository Partners creates specific counterparty exposure: HSA cash held through insurance company partners is not federally insured, and the 10-K notes that contractual arrangements may not be sufficient for members to fully recover assets if a partner fails. The company also disclosed a significant increase in outside fraudulent member account activity in fiscal 2025 and the quarter ended April 30, 2025, resulting in service costs to reimburse impacted members; a consolidated putative class action is pending following a 2024 data breach at a business partner whose user account contained personally identifiable information.
See also: Healthcare · Health Information Services
From HealthEquity, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-10-30Recent Developments — HealthEquity, Inc.
Latest news
- NEWS Lazard Asset Management LLC Sells 9,893 Shares of HealthEquity, Inc. $HQY - MarketBeat — MarketBeat neutral
- NEWS HQY|Healthequity Inc|Price:101.121|Chg%:-3.009 - TradingKey — TradingKey negative
- NEWS Is HealthEquity (HQY) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance — Yahoo Finance positive
- NEWS HealthEquity (HQY) Gains 1.15% as Shares Test Mid-Range Resistance - PCR Extreme - The Legal Advocate — The Legal Advocate positive
- NEWS Expect Equity LLC Purchases New Shares in HealthEquity, Inc. $HQY - MarketBeat — MarketBeat neutral
Generated 2026-10-30T11:27:56Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductHSAs and other CDBs10-K Item 1A: 'Substantially all of our revenue is earned from tax-advantaged HSAs and other CDBs'
- MEDIUMcounterpartyinsurance company partners and Depository Partners48%10-K Item 1A: 'insurance company partners and Depository Partners which comprised approximately 48%, 45%, and 39% of our revenues during the fiscal years ended January 31, 2026, 2025, and 2024'
- LOWProductinterchange fees15%10-K Item 1A: 'We derived 15%, 15%, and 16% of our total revenue during the fiscal years ended January 31, 2026, 2025, and 2024, respectively, from interchange fees'
Material Events(8-K, last 90d)
- 2026-05-08Item 5.02LOWOn May 5, 2026, six named executives — CEO Scott Cutler, CFO James Lucania, Founder/Vice Chairman Stephen Neeleman, CCO Michael Fiore, CPSO Sunil Rajasekar, and General Counsel Delano Ladd — signed amendments to employment agreements providing enhanced severance. No departures; routine compensatory arrangement.SEC filing →
- 2026-04-06Item 5.02MEDIUMCTO Eli Rosner terminated without cause effective April 17, 2026. Technology organization oversight transferred to Sunil Rajasekar (EVP, Chief Product and Strategy Officer since January 2026). Clean handoff named.SEC filing →
- 2026-03-30Item 5.02LOWWilliam Gassen appointed to HealthEquity Board on March 26, 2026. Board expanded to 10 members. Gassen is CEO of Sanford Health, which paid HealthEquity $123,923 in revenues in fiscal year ended January 31, 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $101.36, but acceptable to hold if already in. Reasons: Concentration risk — Product: HSAs and other CDBs; Thin upside margin: 7.1%. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Analyst target $108.60 (+7.1%), stop $95.56 (−6.1%), A.R:R 0.6:1. Score 6.0/10, moderate confidence.
Analyst target: $108.60 (+7.1% upside). Analyst target $108.60 (+7.1%), stop $95.56 (−6.1%), A.R:R 0.6:1. Stop-loss: $95.56.
Concentration risk — Product: HSAs and other CDBs; Thin upside margin: 7.1%.
HealthEquity, Inc. trades at a P/E of 36.6 (forward 18.4). TrendMatrix value score: 5.2/10. Verdict: Hold.
20 analysts cover HQY with a consensus score of 4.3/5. Average price target: $121.
What does HealthEquity, Inc. do?HealthEquity administers HSAs and consumer-directed benefit accounts—17.8 million Total Accounts including 10.6 million...
HealthEquity administers HSAs and consumer-directed benefit accounts—17.8 million Total Accounts including 10.6 million HSAs with $36.5 billion in HSA Assets as of January 2026—and is the largest U.S. HSA provider by account count. Revenue comes from service fees, custodial fees (approximately 48% of FY2026 revenue), and interchange fees (15%), earned through employer and Network Partner relationships.